Natalie Missakian is a Contributing writer for Fierce Biotech. She covers a range of topics with a focus on business, healthcare, and biotechnology, often exploring their impacts on local communities, particularly in relation to government announcements and legal policy regulations. Her work has been featured in New Haven Biz, AARP, Hartford Business Journal, Mainebiz, Fierce Pharma, and Biotech.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Natalie's work shows a keen interest in government announcements, legal policy regulation, and press releases related to healthcare, aging, caregiving, legislation, and AARP. She has a national focus on the United States.
To effectively reach out to Natalie Missakian with relevant pitches or expert commentary, consider offering insights into recent legislative developments impacting older adults' welfare, retirement planning laws or regulations affecting senior citizens. Additionally, providing information about AARP's initiatives and their impact on society could be of interest to her given her coverage of social impact work and advocacy efforts.
Experts well-versed in government policies related to healthcare for seniors or those who can provide unique perspectives on caregiving challenges may also find success when reaching out to Natalie.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Natalie Missakian
As senior director of client services for The Trade Desk, Elizabeth Keenan oversees teams responsible for audience strategy, campaign management and data analytics for the digital media-buying platform's pharmaceutical vertical.
Thermo Fisher Scientific reported “a strong start to the year,” buoyed by strong demand from its pharma and biotech customers, investment in new
By: Natalie Missakian
German drugmaker Merck KGaA is teaming up with Israeli biotech Remepy to develop so-called hybrid drugs that pair a pharmaceutical with a personalized, AI-driven digital component to enhance the th
Transplant-focused precision medicine company CareDx is making a move into the oncology space, scooping up Massachusetts-based biotech Naveris in a deal worth up to $260 million.
By: Natalie Missakian
Johnson & Johnson MedTech is touting positive results from the first clinical study of its Ottava soft-tissue surgical robot, showing the system can safely perform gastric bypass surgery.
While GLP-1s like Ozempic and Wegovy are being widely prescribed for weight loss, doctors currently do not have a way to predict if a patient will successfully respond to the drugs.
By: Natalie Missakian
Scientists know that damage to microscopic blood vessels can provide an early warning sign of heart and kidney disease.
AstraZeneca is the latest Big Pharma company looking to tap into agentic artificial intelligence (AI), inking a three-year licensing deal with Owkin to leverage its autonomous “AI Scientist” platform.
Fujifilm Healthcare Americas Corp. has signed a deal with Ardent Health to bring its enterprise imaging software to hospitals and clinics in six states.
By: Natalie Missakian
For Meghan O’Hora, pharma marketing isn’t about patients. It’s about people and making real connections that help them see beyond their diagnosis toward a healthier future.
